Fact checked by Nick Blackmer Two Alzheimer's drugs that target amlyoid plaques have been approved for months, but many hospitals are only now starting to offer these treatments. Leqembi ...
Eisai is seeking approval for an injectable version of Leqembi while Eli Lilly is developing a new injectable drug. These ...
Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.
Alpha Cognition (ACOG) announced the strategic appointments of Jen Pesa, Vice President of Commercial; Jack Kelly, Head of Market Access; ...
With these key hires, Alpha Cognition is poised to advance its mission of improving the lives of patients and families ...
Italian authorities released the director of a notorious detention camp who had been arrested in Turin on an ICC war crimes warrant. Italian police were acting on an arrest warrant from the ...
Almost finished… We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you. Daily news – Get the most important news from ...
As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...
In July, Vancouver-based Alpha Cognition —a biopharmaceutical company with a North Texas office in Frisco—received FDA approval for its ZUNVEYL oral therapy to treat mild-to-moderate Alzheimer’s ...
The company said this week it remains “on track” to launch ZUNVEYL in the United States in the first quarter of 2025.... North Texas is a big place, with plenty to do, see, hear, and watch. We scour ...
Jan. 15, 2025 — Scientists have come up with a drug that is a potential candidate for tackling memory deficits in the early stages of the disease in rodents. ... New Innovative Local Treatment ...